Chitin and chitinases in SARS-CoV-2 infection

  • Funded by National Institutes of Health (NIH)
  • Total publications:0 publications

Grant number: 1R21AI163640-01A1

Grant search

Key facts

  • Disease

    COVID-19, Other
  • Start & end year

    2023
    2025
  • Known Financial Commitments (USD)

    $194,584
  • Funder

    National Institutes of Health (NIH)
  • Principal Investigator

    Steven Van Dyken
  • Research Location

    United States of America
  • Lead Research Institution

    WASHINGTON UNIVERSITY
  • Research Priority Alignment

    N/A
  • Research Category

    Pathogen: natural history, transmission and diagnostics

  • Research Subcategory

    Immunity

  • Special Interest Tags

    N/A

  • Study Type

    Non-Clinical

  • Clinical Trial Details

    N/A

  • Broad Policy Alignment

    Pending

  • Age Group

    Not Applicable

  • Vulnerable Population

    Not applicable

  • Occupations of Interest

    Not applicable

Abstract

ABSTRACT Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) and resultant coronavirus disease 2019 (COVID-19) has caused a global health crisis, surpassing 100 million infections in the United States. SARS- CoV-2 infections range from asymptomatic to respiratory failure and death, and can result in an array of long- term effects collectively referred to as post-acute sequelae of SARS-CoV-2 infection (PASC). The pathobiological mechanisms and environmental factors underlying the intensity and duration of these effects remain unclear, but a range of chronic lung impairments that resemble complications associated with age-related pulmonary fibrosis have been documented in severe COVID-19, suggesting that environmental drivers implicated in pulmonary fibrosis may also influence the course of SARS-CoV-2 infection and PASC. We have identified the environmental constituent chitin as a candidate environmental driver of persistent SARS-CoV-2- induced disease, consistent with its previously described role in pulmonary fibrosis. Our preliminary studies show that chitin spontaneously accumulates in the lungs of SARS-CoV-2-infected mice, and is accompanied by alterations in the expression patterns of the major lung chitinase, AMCase, suggesting that chitin-chitinase interactions may contribute to SARS-CoV-2 pathogenesis. In comparison with wild-type (WT) controls, mice that genetically lack AMCase exhibit exacerbated lung pathology after infection with SARS-CoV-2, implicating chitin and chitinases in the pathologic sequelae that occur during the recovery phase. Thus, we hypothesize that environmental chitin can drive COVID-19 severity, epithelial dysregulation, and disease persistence, and that epithelial chitinases attenuate this process by degrading chitin. In this project, we leverage recently developed mouse models of SARS-CoV-2 infection and chitin exposure to delineate a host-environmental interaction that may contribute to persistent lung impairments following SARS-CoV-2 infection. We will test our hypothesis by addressing two Aims: (1) determine the influence of environmental chitin on the severity and persistence of lung pathology after SARS-CoV-2 infection, and (2) define the role of mammalian chitinases in SARS-CoV-2 infection and persistent lung disease. Understanding how environmental chitin influences long-lasting pathologic responses after SARS-CoV-2 infection may lead to the identification of new biomarkers and therapeutic targets associated with differential disease outcomes in COVID-19 and PASC.